Global Dexmedetomidine Hydrochloride for Injection Market Research Report 2022

Dexmedetomidine hydrochloride injection is used for sedation during tracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia. COVID-19 broke out globally, and for severe patients, this medicine is a necessity.
Due to the COVID-19 pandemic, the global Dexmedetomidine Hydrochloride for Injection market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Dexmedetomidine Hydrochloride for Injection market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Dexmedetomidine Hydrochloride for Injection landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
100mcg/ml accounting for % of the Dexmedetomidine Hydrochloride for Injection global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Dexmedetomidine Hydrochloride for Injection include Pfizer, Accord Healthcare, Akorn, AuroMedics, Fresenius Kabi, Hikma, Mylan, Par Pharmaceuticals and Sandoz, etc. In terms of revenue, the global 3 largest players have a % market share of Dexmedetomidine Hydrochloride for Injection in 2021.
This report focuses on Dexmedetomidine Hydrochloride for Injection volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Dexmedetomidine Hydrochloride for Injection market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Dexmedetomidine Hydrochloride for Injection Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
100mcg/ml
200mcg/2ml
Segment by Application
Hospital
Clinics
Recovery Center
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Pfizer
Accord Healthcare
Akorn
AuroMedics
Fresenius Kabi
Hikma
Mylan
Par Pharmaceuticals
Sandoz
Sun Pharma
WG Critical Care
Athenex
Cisen Pharmaceutical
Jiangsu Hengrui Pharm
Hunan Kelun Pharmaceutical
Curegen Pharmaceutical